drugset / Trial / NCT06645678
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.
Timeline
- Start
- 2024-11-26
- Primary completion
- 2026-10-01
- Completion
- 2027-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elranatamab | Monoclonal antibody | 76 mg | Subcutaneous |
| Subject | Mezigdomide | Small molecule | — | Oral |
| Background | Dexamethasone | Small molecule | 10 mg | — |